Literature DB >> 34790389

TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer.

Junjie Chen1, Anwaier Apizi2, Lin Wang2, Guanting Wu1, Zheng Zhu1, Huihui Yao1, Guoliang Chen1, Xinyu Shi1, Bo Shi1, Qingliang Tai1, Chenglong Shen3, Guoqiang Zhou3, Lingzhi Wu4, Songbing He1.   

Abstract

BACKGROUND: Colon cancer is one of the most common malignant tumors, with high rates of incidence and death. The tumor mutational burden (TMB), which is characterized by microsatellite instability, has been becoming a powerful predictor which can show tumor behavior and response to immunotherapy.
METHODS: In this study, we analyzed 437 mutation data of colon cancer samples obtained from The Cancer Genome Atlas (TCGA) and divided patients into low- and high-TMB groups according to the TMB value. Then we identified differentially-expressed genes (DEGs), conducted immune cell infiltration and survival analyses between groups.
RESULTS: The higher TMB of the patients with colon cancer predicts a poorer prognosis. Functional analysis was performed to assess the prognostic value of the top 30 core genes. The CIBER-SORT algorithm was used to investigate the correlation between the immune cells and TMB subtypes. An immune prognosis model was constructed to screen out immune genes related to prognosis, and the tumor immunity assessment resource (TIMER) was then used to determine the correlation between gene expression and the abundance of tumor-infiltrating immune cell subsets in colon cancer. We observed that APC, TP53, TTN, KRAS, MUC16, SYNE1, PIK3CA have higher somatic mutations. DEGs enrichment analysis showed that they are involved in the regulation of neuroactive ligand-receptor interaction, the Cyclic adenosine monophosphate (cAMP) signaling pathway, the calcium signaling pathway, and pantothenate and Coenzyme A (CoA) biosynthesis. The difference in the abundance of various white blood cell subtypes showed that Cluster of Differentiation 8 (CD8) T cells (P=0.008), activated CD4 memory T cells (P=0.019), M1 macrophages (P=0.002), follicular helper T cells (P=0.034), activated Natural killer (NK cell) cells (P=0.017) increased remarkably, while M0 macrophages significantly reduced (P=0.025). The two immune model genes showed that secretin (SCT) was negatively correlated with survival, while Guanylate cyclase activator 2A (GUCA2A) was positively correlated.
CONCLUSIONS: This study conducted a systematically comprehensive analysis of the prediction and clinical significance of TMB in colon cancer in identification, monitoring, and prognosis of colon cancer, and providing reference information for immunotherapy. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  TCGA; Tumor mutation burden (TMB); colon cancer; prognosis

Year:  2021        PMID: 34790389      PMCID: PMC8576223          DOI: 10.21037/jgo-21-661

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  50 in total

1.  Immunotherapy of Colon Cancer.

Authors:  Alexander Stein; Gunnar Folprecht
Journal:  Oncol Res Treat       Date:  2018-04-26       Impact factor: 2.825

Review 2.  The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time?

Authors:  Luigi Sapio; Monica Gallo; Michela Illiano; Emilio Chiosi; Daniele Naviglio; Annamaria Spina; Silvio Naviglio
Journal:  J Cell Physiol       Date:  2016-11-20       Impact factor: 6.384

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

5.  Epitope landscape in breast and colorectal cancer.

Authors:  Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

6.  Oncogenic K-Ras suppresses IP₃-dependent Ca²⁺ release through remodelling of the isoform composition of IP₃Rs and ER luminal Ca²⁺ levels in colorectal cancer cell lines.

Authors:  Cristina Pierro; Simon J Cook; Thomas C F Foets; Martin D Bootman; H Llewelyn Roderick
Journal:  J Cell Sci       Date:  2014-02-12       Impact factor: 5.285

Review 7.  Prognostic and predictive roles of KRAS mutation in colorectal cancer.

Authors:  Amanda K Arrington; Eileen L Heinrich; Wendy Lee; Marjun Duldulao; Supriya Patel; Julian Sanchez; Julio Garcia-Aguilar; Joseph Kim
Journal:  Int J Mol Sci       Date:  2012-09-25       Impact factor: 5.923

8.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

9.  Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Authors:  Alexandra Thomas; Eric D Routh; Ashok Pullikuth; Guangxu Jin; Jing Su; Jeff W Chou; Katherine A Hoadley; Cristin Print; Nick Knowlton; Michael A Black; Sandra Demaria; Ena Wang; Davide Bedognetti; Wendell D Jones; Gaurav A Mehta; Michael L Gatza; Charles M Perou; David B Page; Pierre Triozzi; Lance D Miller
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

10.  Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.

Authors:  Xuanwen Bao; Hangyu Zhang; Wei Wu; Shaobing Cheng; Xiaomeng Dai; Xudong Zhu; Qihan Fu; Zhou Tong; Lulu Liu; Yi Zheng; Peng Zhao; Weijia Fang; Fanglong Liu
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.